BDX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 21.47%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Johnson & Johnson's return on equity of 33.27%.

Becton, Dickinson & Co. has a consensus price target of $202.58, signalling upside risk potential of 4.55%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Becton, Dickinson & Co. has higher upside potential than Johnson & Johnson, analysts believe Becton, Dickinson & Co. is more attractive than Johnson & Johnson.

Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Becton, Dickinson & Co. has a quarterly dividend of $1.04 per share corresponding to a yield of 2.15%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.9B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Becton, Dickinson & Co.'s net income of $493M is lower than Johnson & Johnson's net income of $5.2B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.24x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.56x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 26.1%. Becton, Dickinson & Co.'s return on equity of 6.6% beat ResMed, Inc.'s return on equity of 25.6%.

Becton, Dickinson & Co. has a consensus price target of $202.58, signalling upside risk potential of 4.55%. On the other hand ResMed, Inc. has an analysts' consensus of $293.47 which suggests that it could grow by 16.71%. Given that ResMed, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe ResMed, Inc. is more attractive than Becton, Dickinson & Co..

Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Becton, Dickinson & Co. has a quarterly dividend of $1.04 per share corresponding to a yield of 2.15%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Becton, Dickinson & Co.'s net income of $493M is higher than ResMed, Inc.'s net income of $348.5M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.24x while ResMed, Inc.'s PE ratio is 25.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.56x versus 7.04x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 60.4%. Becton, Dickinson & Co.'s return on equity of 6.6% beat Solventum Corp.'s return on equity of 42.2%.

Becton, Dickinson & Co. has a consensus price target of $202.58, signalling upside risk potential of 4.55%. On the other hand Solventum Corp. has an analysts' consensus of $84.36 which suggests that it could fall by -1.04%. Given that Becton, Dickinson & Co. has higher upside potential than Solventum Corp., analysts believe Becton, Dickinson & Co. is more attractive than Solventum Corp..

Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Becton, Dickinson & Co. has a quarterly dividend of $1.04 per share corresponding to a yield of 2.15%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Becton, Dickinson & Co.'s net income of $493M is lower than Solventum Corp.'s net income of $1.3B. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.24x while Solventum Corp.'s PE ratio is 9.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.56x versus 1.77x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 8.37% compared to Becton, Dickinson & Co.'s net margin of 17.41%. Becton, Dickinson & Co.'s return on equity of 6.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Becton, Dickinson & Co. has a consensus price target of $202.58, signalling upside risk potential of 4.55%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 21.72%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..

Becton, Dickinson & Co. has a beta of 0.252, which suggesting that the stock is 74.828% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Becton, Dickinson & Co. has a quarterly dividend of $1.04 per share corresponding to a yield of 2.15%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Becton, Dickinson & Co. pays 71.53% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton, Dickinson & Co. quarterly revenues are $5.9B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Becton, Dickinson & Co.'s net income of $493M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Becton, Dickinson & Co.'s price-to-earnings ratio is 33.24x while West Pharmaceutical Services, Inc.'s PE ratio is 42.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton, Dickinson & Co. is 2.56x versus 6.86x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.